Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 55,000
- Avg volume
- —
- Day's range
- $0.05 – $0.05
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and internationally. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InRe...
Show more
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and internationally. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InReach, a point-of-care extremity CT imaging which assess the distal extremities with 3D clarity at a fraction of the dose; and CubeVue Software visualization tools. It also provides software CurveBeam AI Autometrics for automatically segment foot and ankle datasets; Axiometrics, provides a semi-automatic measurement of the axes of rotation of the hip, femur, knee, and ankle; and TALAS, a measurement tool that semi-automatically calculate hindfoot alignment based on reproducible three-dimensional anatomical landmarks. In addition, the company offers custom web-based cloud platform; and OSSView. The company was incorporated in 2009 and is headquartered in Hatfield, Pennsylvania.
- Industry
- Medical Devices
- Sector
- Healthcare
- Phone
- 267 483 8081
- Website
- https://curvebeamai.com
- Address
- 2800 Bronze Drive, Suite 110, Hatfield, United States
Latest news
No headlines yet.